Contact the Editorial Desk

Editorial correspondence

Youth Lab Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial, a regulatory status update, or a peer-reviewed study on BPC-157, NAD+, semaglutide, or Thymosin Alpha-1 that should be added to the references page. The most actionable messages specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed ID where possible — so the proposed change can be verified against its source.

Editorial mailbox: editors@youthlabpeptides.com

What this desk cannot do

So that no message goes unanswered for the wrong reason: this is a literature digest, not a clinical service, so it cannot advise on or recommend human use of any compound discussed here, suggest a dose or schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate a supplier of any compound. Semaglutide is a prescription medicine available only through a licensed provider; BPC-157 is not approved for human use anywhere. Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed.